SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held biotechnology company, today announced that it will unveil the results of its Phase I/II trial of KAI-9803 (DELTA-MI) in a Late-Breaking Session of the 56th Annual Scientific Session of the American College of Cardiology (ACC), March 25, 2007 at 11:30 a.m. in New Orleans at the i-2 Intervention Summit. Dr. Matthew Roe from the Duke Clinical Research Institute in Durham, North Carolina, the study’s principal investigator, will present the results of the 154-patient trial, which was completed in November, 2006.
